To include your compound in the COVID-19 Resource Center, submit it here.

Vivus falls on expected CHMP negative opinion

Vivus Inc. (NASDAQ:VVUS) fell $2.72 (11%) to $21 on Friday after the company said it expects EMA's CHMP to

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE